Tokyo Tape
Sign in
← Vital Ksk Holdings

Quarterly report · Q1

3151.TEDINET S100OW8K
Period2022-04-01 → 2022-06-30
Filed2022-08-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥143.5bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥577.2bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥142.9bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥452m2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥377m2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥1.2bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥5.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.1bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥1.1bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥1.1bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥640m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥644m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥675m2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥674m2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥314.2bnat 2022-06-30Cons.Assets
Total assets¥313.0bnat 2022-03-31Cons.Assets
Total assets¥333.7bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥212.9bnat 2022-06-30Cons.Liabilities
Total liabilities¥213.0bnat 2022-03-31Cons.Liabilities
Net assets / equity¥101.4bnat 2022-06-30Cons.Net assets
Net assets / equity¥100.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥106.1bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥27.9bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥27.0bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥12.052022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥87.882021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥11.672021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio31.9%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio31.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.5%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥626m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30−¥69m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.4bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue2022-04-01 → 2022-06-30¥138.0bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue external2022-04-01 → 2022-06-30¥135.2bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥2.8bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentsegment profit2022-04-01 → 2022-06-30¥389m
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥14m
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.7bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.7bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥118m
—segment totalrevenue2022-04-01 → 2022-06-30¥145.1bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥142.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥2.8bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥521m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥146.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥143.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥452m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-06-30¥1.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-06-30¥1.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-06-30¥626m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-06-30−¥45m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥2.8bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥2.8bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥13m
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue2021-04-01 → 2021-06-30¥137.0bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue external2021-04-01 → 2021-06-30¥134.8bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥2.2bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentsegment profit2021-04-01 → 2021-06-30¥290m
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥4.4bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥4.4bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥1m
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥39m
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥2.6bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥2.6bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥0
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥106m
—segment totalrevenue2021-04-01 → 2021-06-30¥144.0bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥141.8bn
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥2.2bn
—segment totalsegment profit2021-04-01 → 2021-06-30¥437m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥145.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥142.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥2.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥391m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 370
ItemContextValueUnit
Selling general and administrative expensesPrior1YTDDuration9843000000JPY
Selling general and administrative expensesCurrentYTDDuration10282000000JPY
Operating incomePrior1YTDDuration377000000JPY
Operating incomeCurrentYTDDuration452000000JPY
Interest income noiPrior1YTDDuration11000000JPY
Interest income noiCurrentYTDDuration15000000JPY
Dividends income noiPrior1YTDDuration178000000JPY
Dividends income noiCurrentYTDDuration185000000JPY
Equity in earnings of affiliates noiPrior1YTDDuration3000000JPY
Equity in earnings of affiliates noiCurrentYTDDuration24000000JPY
Office work fee noiPrior1YTDDuration390000000JPY
Office work fee noiCurrentYTDDuration397000000JPY
Other noiPrior1YTDDuration158000000JPY
Other noiCurrentYTDDuration173000000JPY
Non operating incomePrior1YTDDuration742000000JPY
Non operating incomeCurrentYTDDuration795000000JPY
Interest expenses noePrior1YTDDuration24000000JPY
Interest expenses noeCurrentYTDDuration26000000JPY
Rent expenses noePrior1YTDDuration21000000JPY
Rent expenses noeCurrentYTDDuration20000000JPY
Other noePrior1YTDDuration7000000JPY
Other noeCurrentYTDDuration3000000JPY
Non operating expensesPrior1YTDDuration53000000JPY
Non operating expensesCurrentYTDDuration49000000JPY
Ordinary incomePrior1YTDDuration1067000000JPY
Ordinary incomeCurrentYTDDuration1198000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration11000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration3000000JPY
Other eiPrior1YTDDuration0JPY
Other eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration11000000JPY
Extraordinary incomeCurrentYTDDuration3000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration19000000JPY
Loss on sales of noncurrent assets elCurrentYTDDuration－JPY
Loss on valuation of investment securities elPrior1YTDDuration－JPY
Loss on valuation of investment securities elCurrentYTDDuration55000000JPY
Soil removal expenses elPrior1YTDDuration－JPY
Soil removal expenses elCurrentYTDDuration62000000JPY
Other elPrior1YTDDuration1000000JPY
Other elCurrentYTDDuration2000000JPY
Extraordinary lossPrior1YTDDuration21000000JPY
Extraordinary lossCurrentYTDDuration119000000JPY
Income before income taxesPrior1YTDDuration1057000000JPY
Income before income taxesCurrentYTDDuration1081000000JPY
Income taxesPrior1YTDDuration383000000JPY
Income taxesCurrentYTDDuration406000000JPY
Profit lossPrior1YTDDuration674000000JPY
Profit lossCurrentYTDDuration675000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration29000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration35000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass